H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $27 and keeps a Buy rating on the shares. The firm expects veligrotug to meet the endpoints in chronic thyroid eye given that Tepezza demonstrated efficacy in chronic TED treatment. It thinks veligrotug will show at least comparable efficacy to Tepezza.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Therapeutics Reports Increased Cash Reserves Amid Losses
- Viridian Therapeutics Advances in Biotech Innovations
- Viridian Therapeutics reports Q3 EPS ($1.15), consensus ($1.06)
- Is VRDN a Buy, Before Earnings?
- Viridian Therapeutics management to meet with Jefferies
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
